CNSP — CNS Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $2.92m
- -$9.91m
Annual income statement for CNS Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 9.45 | 14.5 | 15.3 | 18.9 | 14.9 |
| Operating Profit | -9.45 | -14.5 | -15.3 | -18.9 | -14.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -9.46 | -14.5 | -15.3 | -18.9 | -14.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -9.46 | -14.5 | -15.3 | -18.9 | -14.9 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.46 | -14.5 | -15.3 | -18.9 | -14.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.46 | -14.5 | -15.3 | -18.9 | -14.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -356,859 | -495,050 | -336,513 | -150,120 | -466 |